MAPT and Alzheimer disease: A previous publication by our group using the same cohort but few participants showed Aβ42 and tau levels at 3 months were lower in the patients with PSCI at 1 year than in those without PSCI, which may reveal AD pathology one mechanism of PSCI development after 3 months of stroke and decreased levels of plasma tau could be explained by its association with the decreased plasma Aβ42 levels (Chi et al., 2019).